Therapeutics Company Receives FDA Fast Track Designation For Prostate Cancer Treatment

BioXcel Therapeutics' BXCL701 Receives FDA Fast Track Designation: A New Hope in the Battle Against Small Cell Neuroendocrine Prostate Cancer.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission. This article is not intended to provide medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical …